Indivior PLC 78.8% potential upside indicated by Deutsche

Indivior PLC with ticker (LON:INDV) now has a potential upside of 78.8% according to Deutsche.

INDV.L

Deutsche set a target price of 1,500 GBX for the company, which when compared to the Indivior PLC share price of 839 GBX at opening today (06/09/2024) indicates a potential upside of 78.8%. Trading has ranged between 653 (52 week low) and 1,877 (52 week high) with an average of 722,163 shares exchanging hands daily. The market capitalisation at the time of writing is £1,054,314,096.

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.